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Abstract
Introduction: To evaluate the clinical profile of BIAsp 30 (30% soluble insulin aspart, 70% protamine-crystallized insulin aspart) (NovoMix®30)
in type 2 diabetes patients in routine clinical practice in Iran.
Material and methods: IMPROVE™ was a 26-week, multinational, open-label, non-randomized study in patients with type 2 diabetes.
The safety and efficacy of BIAsp 30 were assessed at baseline and at 13 and 26 weeks. The titration of BIAsp30 was at the physician’s
discretion.
Results: In Iran, 478 patients (47% male) previously treated with oral antidiabetic drugs (OADs) (N = 159, 33.3%) and/or insulin other than
BIAsp30 (N = 317, 66.3%) or a few who were treatment-naïve (N = 2, 0.4%) participated in the study. After 26 weeks of treatment with
BIAsp 30, the rate of reported major hypoglycaemic episodes was reduced by 88.1% from baseline (baseline v. Week 26: 0.303 v. 0.037
episodes/pt-year; p < 0.001). No significant differences in minor hypoglycaemic episodes between baseline and Week 26 were found.
Glycaemic control was significantly improved from baseline to Week 26 with a mean HbA1c reduction of 1.2 ± 1.9%. Patients’ quality of life
as measured by the DiabMedSat questionnaire significantly improved from baseline (58.1) to the end of the study (75.4, p < 0.001).
Conclusions: BIAsp 30 therapy appeared safe and effective and improved quality of life in Iranian patients with type 2 diabetes after
26 weeks of treatment. (Pol J Endocrinol 2010; 61 (4): 364–370)
Key words: type 2 diabetes, insulin aspart, quality of life
Streszczenie
Wstęp: Celem badania była ocena profilu działania insuliny BIAsp 30 (30% rozpuszczalnej insuliny aspart, 70% insuliny krystalizowanej
z protaminą) (NovoMix®30) u chorych na cukrzycę typu 2 w warunkach standardowej opieki zdrowotnej w Iranie.
Materiał i metody: IMPROVE™ było 26-tygodniowym, wieloośrodkowym, międzynarodowym, otwartym i nierandomizowanym bada-
niem z udziałem chorych na cukrzycę typu 2. Bezpieczeństwo i skuteczność insulin BIAsp 30 oceniano na początku badania oraz po
13 i 26 tygodniach. Dawkowanie insuliny BIAsp30 było zależne od zaleceń lekarskich.
Wyniki: W irańskiej części badania uczestniczyło 478 chorych (47% stanowili mężczyźni) leczonych dotychczas doustnymi lekami hipo-
glikemizującymi (N = 159, 33.3%) i/lub insuliną inną niż BIAsp30 (N = 317, 66,3%) oraz nieliczna grupa pacjentów niestosujących wcześ-
niej farmakoterapii (N = 2, 0,4%). Po 26 tygodniach leczenia insuliną BIAsp 30, częstość epizodów ciężkiej hipoglikemii zmniejszyła się
o 88,1% (wartości wyjściowe v. tydzień 26: 0,303 v. 0,037 epizodów/pacjenta-rok; p < 0,001). Dane dotyczące częstości epizodów lekkiej
hipoglikemii na początku badania i po 26 tygodniach leczenia nie różniły się istotnie. Odnotowano natomiast poprawę kontroli glikemii;
po 26 tygodniach odsetek HbA1c obniżył się średnio o 1,2 ± 1,9% w stosunku do wartości wyjściowej. W okresie od rozpoczęcia do zakoń-
czenia badania nastąpiła istotna poprawa jakości życia chorych, oceniana przy użyciu kwestionariusza DiabMedSat; punktacja wynosiła
odpowiednio 58,1 i 75,4 (p < 0,001).
Wnioski: Terapia insuliną BIAsp 30 stosowana przez 26 tygodni u Irańczyków chorych na cukrzycę typu 2 okazała się bezpieczna i skutecz-
na, a ponadto spowodowała poprawę jakości życia pacjentów. (Endokrynol Pol 2010; 61 (4): 364–370)
Słowa kluczowe: cukrzyca typu 2, insulina aspart, jakość życia
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Introduction
Therapy for type 2 diabetes has been focused on con-
trolling fasting blood glucose (FBG) with oral antidia-
betic drugs (OAD) and/or basal insulin [1]. As type 2
diabetes progresses, treatment strategies focusing on
basal insulin combined with OADs are limited in their
effectiveness due to the lack of provision for prandial
insulin requirements. Hence, postprandial hyperglycae-
mia is becoming a significant contributor to overall gly-
caemic load. On the other hand, the relative contribu-
tion of postprandial glucose excursions is predominant
in moderately controlled patients, whereas the contri-
bution of fasting hyperglycaemia increases gradually
with diabetes progression [2].
It is well established that incidence and progression
of diabetic microvascular complications are correlated
with the status of glycaemic control. Improved long-
term glycaemic control (lower HbA1c) has also been
shown to be associated with a reduction in cardiovas-
cular risks [3–8].
Metformin, in combination with diet and exercise,
is recommended as a first line treatment for patients
with type 2 diabetes by the American Diabetes Associa-
tion (ADA) and the European Association for the Study
of Diabetes (EASD). Upon progression of type 2 diabe-
tes, metformin is often combined with insulin secreta-
gogues (e.g. sulphonylureas such as glimepiride) or
peroxisome proliferator-activated receptor agonists (e.g.
thiazolidinediones such as rosiglitazone). Insulin ther-
apy, as add-on or monotherapy, is indicated for sub-
jects who do not achieve good glycaemic control de-
spite this OAD combination therapy. However, ADA/
/EASD also recommends the addition of insulin times
when appropriate glycaemic control cannot be obtained
with metformin mono-therapy alone in patients with
type 2 diabetes [9].
Biphasic insulin aspart 30 (BIAsp 30) (NovoMix®30)
is a premixed insulin analogue containing 30% unbound
rapid-acting insulin aspart and 70% protaminated in-
termediate-acting insulin aspart. This premix formula-
tion provides prandial and basal insulin coverage after
one injection . The rapid onset of action of BIAsp 30
means that it can be injected immediately before or with-
in 15 minutes of meal start [11], in contrast to biphasic
human insulin which should be injected 30 minutes
before a meal [12]. Garber  et al. [13] demonstrated that
the initiation of once daily treatment (and intense titra-
tion) with BIAsp 30 in combination with OADs enabled
41% of patients to achieve HbA1c £ 7.0% , the ADA gly-
caemic target for patients with diabetes . More patients
could safely achieve these goals when the number of
daily injections was increased from one to two and from
two to three. With three daily injections of BIAsp 30,
good glycaemic control was achieved in 77% (HbA1c
< 7.0%) of patients. In a treat-to-target study with insu-
lin-naïve patients with type 2 diabetes poorly controlled
with metformin (alone or in combination with other
OADs), significantly more patients treated with BIAsp
30 twice daily than those treated once daily with insu-
lin glargine achieved an HbA1c < 7.0% (66% v. 40%,
p < 0.05) [15]. The similar findings were also obtained
in another study, in insulin-naïve patients with type 2
diabetes poorly controlled with OADs (twice-daily
BIAsp 30 plus metformin v. once-daily insulin glargine
plus glimepiride) [16].
Limited information about diabetes in Iran was avail-
able except recent epidemiological and cost data of dia-
betes in the Iranian population which indicates the prev-
alence of diabetes mellitus as 8.7% (age 25 to 64) with
3 times more direct costs for diabetics compared to non-
diabetic patients [17–18]. Although the efficacy and safe-
ty of BIAsp 30 have been extensively documented in
randomized clinical trials (RCTs) [13, 15–16, 19–22], there
was no data regarding the use of BIAsp 30 in patients
from Iran. Observational studies are a valuable tool for
assessing the effectiveness and safety of drugs in a wide
and heterogeneous population, without the confines of
an RCT [23–24].
This observational study aimed to evaluate the clin-
ical safety profile and efficacy of BIAsp 30 under nor-
mal clinical practice conditions in Iran.
Material and methods
Study design
IMPROVETM is a 26-week, open-label, non-randomised,
multi-centre observational study of patients with type 2
diabetes conducted in 11 countries (Canada, China,
Greece, the Gulf region, India, Iran, Italy, Japan, Poland,
Russia, and South Korea), as described in previous pub-
lications [19, 21]. The study included patients with type
2 diabetes who were 18 years old and above treated with
BIAsp 30 in routine clinical practice.
Results from the Iranian subgroup are reported in
this paper. BIAsp 30 (100 IU/mL) was prescribed by the
physician in routine clinical evaluations. The starting
dose and frequency of injection, as well as subsequent
dose adjustments, were individualised and were at the
discretion of the physician. No study-specific investi-
gations were involved except the collection of data at
baseline, follow-up visit (approximately 13 weeks), and
final visit (approximately 26 weeks). The study was con-
ducted in accordance with the Declaration of Helsinki.
The procedures complied with local regulations gov-
erning observational studies, which were applicable to
health authority and ethics committee approval and
patient informed consent.
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Measurements
The primary endpoint was the incidence of major hy-
poglycaemic events reported as serious adverse drug
reactions (SADRs). A major hypoglycaemic episode was
defined as an episode with severe central nervous sys-
tem symptoms consistent with hypoglycaemia, in which
the patient was unable to treat him/herself and had one
measurement of blood glucose < 50 mg/dL (2.8 mmol/L)
or reversal of symptoms after either food intake or glu-
cagon or intravenous glucose administration. A minor
hypoglycaemic episode was defined as an episode with
symptoms of hypoglycaemia with the confirmation of
blood glucose measurement < 56 mg/dL (3.1 mmol/L)
and which was handled by the patient or any asymp-
tomatic blood glucose measurement < 56 mg/dL
(3.1 mmol/L).
The secondary endpoints included the number of
SADRs, the number of minor hypoglycaemic episodes,
changes in body weight and body mass index (BMI),
HbA1c, fasting blood glucose (FBG), the variability in
FBG, post prandial glucose (PPG) after all main meals,
and treatment satisfaction as assessed by the Diabetes
Medication Satisfaction (DiabMedSat) questionnaire
(0 to 100-point scale with higher scores indicating higher
quality of life) .This questionnaire had been translated
into Farsi (Persian) and also validated in a subgroup of
patients.
Statistical analyses
In this study, data were summarised by visits including
baseline and Week 26. The summary of the baseline
characteristics and safety data were based on a Full
Analysis Set (FAS), which consisted of all patients with
a baseline visit, who had been prescribed BIAsp 30 at
least once and did not use BIAsp 30 before the start of
the study. The analysis of the efficacy outcome variables
were based on an Efficacy Analysis Set (EAS), which
was defined as all patients from FAS who had the Week
26 visit, at least one measurement concerning FBG, PPG,
most recent HbA1c, weight, or hypoglycaemic episodes
at baseline and Week 26, with the final visit within 18 to
31 weeks from baseline. The analysis of the quality of
life (QoL) data was based on a Quality of Life Analysis
Set (QLAS), which was defined as all patients from FAS
who were treated before the study with either OAD or
insulin and who had completed at least one item of the
DiabMed questionnaire at baseline and Week 26.
Descriptive statistics were used to summarise the
absolute number of hypoglycaemic episodes, and hy-
poglycaemic episodes were expressed as both the ab-
solute number of episodes and the number of episodes
per patient years. The Wilcoxon signed rank test was
used to compare the number of hypoglycaemic episodes
at baseline and Week 26. Descriptive statistics were used
to summarise HbA1c, mean FBG and FBG variability,
and mean PPG and PPG variability. The proportion of
patients who achieved HbA1c £ 6.5%, HbA1c < 7.0%,
and physician’s own target recommendation for HbA1c
was summarised using percentages. Paired t-test was
used to compare HbA1c, mean FBG, and FBG variabil-
ity values at baseline and Week 26. The test was per-
formed only if values at both visits were present. Dis-
crete variables were displayed in frequency tables. All
testing used two-sided tests with significance level
a = 0.05 and were performed using SAS, Version 9.1
(SAS Institute, Cary, NC).
Results
Baseline Demographics
A total of 479 patients were enrolled by 5 centres and
9 independent investigators from Tehran, Isfahan, Yazd,
Tabriz, and Mashhad in Iran. One of the patients had
biphasic insulin aspart treatment prior to the study and
was excluded from the study. Included in the analysis
were 478 patients, and 435 of them completed the study.
The demographic characteristics of all patients and the
reasons for initiating new therapy are summarised in
Table I. The patients had a mean age of 55.2 ± 11.8 years,
with a slightly higher proportion of females (male: fe-
male = 47/53%). Mean BMI was 28.1 ± 4.8 kg/m2 and
mean diabetes duration was 13.2 ± 8.2 years. Macrovas-
cular complications (41.6%) and microvascular compli-
cations (61.1%) were commonly reported by the pa-
Table I. Baseline characteristics
Tabela I. Charakterystyka badanych
Total
N 478
Mean age ± SD (years) 55.3±11.8
Gender, M/F (%) 47/53
Mean weight ± SD [kg] 75.3±14.3
Mean BMI ± SD [kg/m2] 28.1±4.8
Mean diabetes duration ± SD (years) 13.2±8.2
Mean HbA1c ± SD (%) 8.6±2.0
Macrovascular Complications 41.6%
Peripheral vascular disease 6.0%
Coronary heart disease 37.8%
Stroke 4.4%
Microvascular Complications 61.1%
Retinopathy 31.8%
Diabetic nephropathy 22.2%
Peripheral neuropathy 37.7%
Autonomic neuropathy 7.1%
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tients. The majority of the patients (N = 317, 66.3%)
were previously treated with Insulin ± OAD, of which
34.7% were treated with insulin only and 31.6% with
both insulin and OAD. Overall, 0.4% (N = 2) of patients
were pharmacological intervention naive and 33.3%
(N = 159) were previously treated with OAD only.
The most cited reason for starting new therapy was
to improve glycaemic control (to improve FBG: 64.6%,
to improve PPG: 60.9%, to improve HbA1c: 57.1%)
(Table II). The mean daily dose of BIAsp 30 after enter-
ing into the study (baseline) was 33.3 IU (0.44 IU/kg)
and increased to 55.7 IU (0.70 IU/kg) at Week 26. The
majority of patients injected BIAsp 30 on average twice
daily throughout the study period (74.1% at baseline
and 64.6% at Week 26). Patients were exposed to BIAsp 30
for approximately 27 weeks.
Safety
The proportion of patients with major hypoglycaemic
episodes which were reported as SADRs during the
study was 0.4%. The proportion of patients who report-
ed major hypoglycaemic episodes decreased over time:
from 4.4% at baseline to 0.5% at Week 26. The same
trends were seen for daytime major episodes (2.9% at
baseline to 0 at Week 26) and nocturnal episodes (2.1%
at baseline to 0.5% at Week 26). In contrast, the propor-
tion of patients reporting minor hypoglycaemic epi-
sodes did not change across the study period (37% at
baseline and 34.7% at Week 26 visit), regardless of the
time of occurrence (daytime or nocturnal episodes).
Major and minor hypoglycaemic episodes are also
summarised as episodes/patient year in Figure 1. The
total number of major hypoglycaemic episodes de-
creased from 0.303 episodes/patient year at baseline to
0.037 episodes/patient year at Week 26. Both daytime
(baseline: 0.184 episodes/patient year, Week 26:
Table II. Reason(s) for starting new therapy
Tabela II. Powody rozpoczęcia nowej terapii
Reason(s) for starting new therapy, n (%) Total
 Easy Start of Insulin Therapy 190 (39.7)
Easy Intensification of Insulin Therapy 77 (16.1)
Improve HbA1c 273 (57.1)
Improve FBG 309 (64.6)
Improve PPG 291 (60.9)
Reduce Risk of Hypoglycaemia 125 (26.2)
Patient Dissatisfaction with Previous Therapy 187 (39.1)
Side Effects from Previous Therapy 35 (7.3)
Change Due To Insulin Pen 250 (52.3)
Allow For Mealtime Administration 142 (29.7)
Percentages are based on the number of subjects with non-missing
values; A subject may have findings in more than one category in
Reason(s) for starting new therapy
Figure 2. Number of hypoglycaemic episodes (episodes/patient years)
Rycina 2. Liczba epizodów hipoglikemii (epizod/pacjent/rok)
Figure 1. Weight change by BMI groups
Rycina 1. Zmiana ciężaru ciała w zależności od wskaźnika BMI
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0.028 episodes/patient year) and nocturnal (baseline:
0.120 episodes/patient year, Week 26: 0.009 episodes/pa-
tient year) major episodes also decreased. Daytime mi-
nor hypoglycaemic episodes decreased from 11.685 epi-
sodes/patient year at baseline to 8.906 episodes/patient
year at Week 26. No differences between baseline and
Week 26 were found in overall minor hypoglycaemic
episodes and nocturnal minor hypoglycaemic episodes.
Efficacy
HbA1c was significantly reduced by 1.24 ± 1.85% from
baseline to Week 26. FBG was significantly reduced by
3.00 ± 3.95 mmol/L at Week 26. Moreover, the mean
value of FBG variability was significantly reduced by
0.60 ± 1.56 mmol/L at Week 26 (Table III). A significant
decrease was also observed in PPG at breakfast, lunch,
and dinner (Table III).
Body weight
The mean values of body weight and BMI over time
and the change from baseline to Week 26 are sum-
marised in Table III. Body weight was significantly in-
creased at Week 26 by 1.67 ± 4.86 kg. Accordingly,
BMI was significantly increased at Week 26 by 0.66 ±
± 1.86 kg/m2. The change in body weight from baseline
to Week 26 by various BMI groups at baseline is shown
in Figure 2. It is observed that the increase in body
weight from baseline to the end of treatment appeared
to be greater with decreasing baseline BMI.
Patient satisfaction
The overall total DiabMedSat score after 26 weeks was
significantly higher than that of baseline (baseline v.
Week 26: 58.1 v. 75.4, p < 0.001) (Table III). All three
subscale scores of DiabMedSat, “burden”, “symptoms”,
and “efficacy” at Week 26 were increased in contrast to
that of baseline, with the greatest improvement in the
‘efficacy’ subscale (baseline v. Week 26: 42.1 v. 72.6,
p < 0.001) (Table III).
Discussion
The IMPROVE™ study was a 26-week, multi-nation-
al, observational study in patients with type 2 diabetes,
conducted to evaluate the clinical profile of BIAsp 30 in
routine clinical practice. The safety and efficacy of BI-
Asp 30 were assessed at baseline and at Week 26. The
results achieved in this study of the Iranian cohort of
the IMPROVE™ study show that BIAsp 30 was safe, ef-
fective, and improved the quality of life in patients with
type 2 diabetes. These results are in concordance with
the findings in randomised clinical trials [12–13, 15–16,
26] as well as with the IMPROVE™ studies conducted
in other countries [19–22].
The primary endpoint in this observational study
was the incidence of major hypoglycaemic episodes
reported as SADRs. The proportion of patients with
major hypoglycaemic episodes which were reported as
SADRs during the study was 0.4%. An association of
Table III. Change from baseline in efficacy parameters
Tabela III. Zmiany parametrów skuteczności terapii w stosunku do wartości wyjściowych
Parameter (SD) Baseline Week 26 Absolute change
Mean HbA1c, %Hb 8.6 (2.0) 7.4 (1.2) –1.2 (1.9)
*
Mean FBG [mmol/L] 10.7 (3.8) 7.7 (2.3) –3.0 (4.0)*
Mean PPG, mmol/L
At breakfast 14.8 (5.1) 9.8 (2.9) –5.0 (5.1)*
At lunch 12.4 (5.3) 9.9 (3.6) –2.6 (5.4)*
At dinner 11.9 (4.6) 9.2 (2.3) –2.7 (4.0)*
Body weight, kg 75.6 (14.5) 77.2 (14.3) +1.7 (4.0)*
BMI [kg/m2] 28.2 (4.8) 28.9 (4.9) +0.7 (.9)*
DiabMedSat
Overall score 58.1 (12.7) 75.4 (12.0) +17.3 (16.0)*
Relief of burden 68.9 (15.8) 83.0 (12.6) +14.1 (18.5)*
Relief of symptoms 63.8 (15.8) 71.2 (15.9) +7.4 (20.2)*
Effectiveness 42.1 (19.4) 72.6 (17.3) +30.5 (25.0)*
* p < 0.001; FBG — fasting blood glucose; PPG — post prandial glucose; NS — not significant
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increased risk of hypoglycaemia and tight glycaemic
control was demonstrated in previous studies. How-
ever, in this study although both fasting and post pran-
dial glycaemic control was improved during the
26-week treatment with BIAsp 30, the number of hypo-
glycaemic episodes reported was significantly reduced
over time, with most episodes occurring during the first
13 weeks of treatment. The safety profile observed in
this study was consistent with the safety profile in the
global IMPROVE™ study in which, generally, there was
a lower risk of major hypoglycaemia (reduced from
baseline by 89% after 26 weeks in the Iranian cohort
and by 94% in global results) [22]. In line with the glo-
bal IMPROVE™ study, no differences were found in
minor hypoglycaemic episodes [22].
Treatment with BIAsp 30 enabled Iranian patients
with type 2 diabetes to reach a mean HbA1c of 7.39%
after 26 weeks of treatment (mean baseline: 8.63%) with
a mean reduction of 1.24%. For the global cohort, mean
HbA1c was decreased from 9.3% at baseline to 7.1% at
Week 26 [22]. The greater mean reduction in HbA1c in
the global cohort could be explained by the larger por-
tion of patients with no or OAD-only pretreatment in
the global cohort. In the global cohort, 17.1% patients
had received no previous treatment and 64.5% were
on OAD only (v. 0.4% and 33%, respectively, in the Iran
subgroup).
In line with the global results, FBG, the mean value
of FBG variability, and PPG decreased significantly from
baseline after the treatment with BIAsp 30. Therefore,
BIAsp 30 not only provides basal insulin coverage but
also effectively controls the postprandial component of
glycaemic parameters, consistent with the finding in
clinical trials [26].
An increase in body weight of 1.7 kg was observed
after 26 weeks of treatment with BIAsp 30 in Iranian
patients, while in the global IMPROVE™ study, weight
changed very little from baseline to Week 26 (–0.1 kg)
[22]. The discrepancy between the Iran cohort and glo-
bal results might be due to the ethnic difference since
the baseline BMI and the change in body weight varied
greatly within countries in the IMPROVE™ study. It is
indicated that further cross-ethnic comparisons are
needed for better understanding of the relationship
between BIAsp 30 and body weight.
The overall total DiabMedSat score after 26 weeks
was significantly higher than at baseline (baseline v.
Week 26: 58.1 v. 75.4), which is consistent with the glo-
bal study (57.2 v. 74.5) [22]. The most cited reason for
starting new therapy was to improve glycaemic con-
trol, indicating that patients were most dissatisfied with
the efficacy of their previous treatments prior to the
study. After 26 weeks’ treatment with BIAsp 30, all three
subscale scores of DiabMedSat, “burden”, “symptoms”,
and “efficacy” were increased from baseline, with the
greatest enhancement in the ‘efficacy’ subscale. The re-
sults indicated that treatment with BIAsp 30 significantly
improved patient satisfaction and their quality of life.
Although limitations existed in this study in terms
of a lack of control groups or tightly controlled popula-
tions and the potential recall bias in retrospective data
collection, the better understanding of the safety and
effectiveness of BIAsp 30 in routine clinical practice
served as a valuable part for confirming the results from
controlled clinical studies.
Conclusions
In routine clinical practice in Iran, treatment with BI-
Asp 30 can improve glycaemic control without increas-
ing hypoglycaemic episodes in poorly controlled Irani-
an patients with type 2 diabetes. In addition, the im-
provement of overall treatment satisfaction may en-
hance patient adherence and self-management.
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